首页> 外文OA文献 >Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

【2h】

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

机译：Trebananib（AMG 386）加每周紫杉醇联合或不联合贝伐单抗作为HER2阴性局部复发或转移性乳腺癌的一线治疗：一项2期随机研究

页面导航

摘要
著录项
相似文献
相关主题

摘要

status: published

机译：状态：已发布

著录项

作者
Dieras Veronique; Wildiers Hans; Jassem Jacek; Dirix Luc Y; Guastalla Jean-Paul; Bono Petri; Hurvitz Sara A; Goncalves Anthony; Romieu Gilles; Limentani Steven A; Jerusalem Guy; Lakshmaiah K. C; Roche Henri; Sanchez-Rovira Pedro; Pienkowski Tadeusz; Segui Palmer Miguel Angel; Li Ai; Sun Yu-Nien; Pickett Cheryl A; Slamon Dennis J;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019 ,第008期
2. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study [J] . Dieras Veronique, Wildiers Hans, Jassem Jacek, The Breast : . 2015 ,第3期

机译：Trebananib（AMG 386）加每周紫杉醇联合或不联合贝伐单抗作为HER2阴性的局部复发或转移性乳腺癌的一线治疗：一项2期随机研究
3. CALGB 40502/NCCTG N063H: Randomized Phase III Trial of Weekly Paclitaxel (P) Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel (NP) or Ixabepilone (Ix) With or Without Bevacizumab (B) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (MBC) [J] . Clinical advances in hematology & oncology: H&O . 2012 ,第Suppla14期

机译：CALGB 40502 / NCCTG N063H：每周一次紫杉醇（P）与每周一次纳米粒白蛋白结合的纳布-紫杉醇（NP）或伊沙贝比隆（Ix）进行或不使用贝伐单抗（B）作为局部复发或转移性一线治疗的随机III期试验乳腺癌（MBC）
4. 5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial [J] . I.Lang, M.Inbar, G.Steger, European Journal of Cancer Supplements . 2009 ,第2期

机译：5058贝伐单抗（Bev）联合卡培他滨（X）或每周紫杉醇（Pac）作为HER2阴性的局部复发或转移性乳腺癌（LR / MBC）的一线治疗：CECOG III期TURANDOT试验
5. Weekly Paclitaxel Therapy as the Second-line Chemotherapy to TS-1 for Advanced/Metastatic Gastric Cancer [C] . M. Fujishima, H. Imamura, H. Furukawa, International Gastric Cancer Congress . 2005

机译：每周紫杉醇治疗作为先进/转移性胃癌的二线化学疗法至TS-1
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) [O] . Hope S. Rugo, William T. Barry, Alvaro Moreno-Aspitia, -1

机译：每周一次紫杉醇与绑定纳米白蛋白的Nab-紫杉醇每周一次或与伊沙贝比隆联合贝伐单抗作为局部复发或转移性乳腺癌的一线化疗的随机III期试验：CALGB 40502 / NCCTG N063H（联盟）
8. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer [O] . Vrdoljak E., Marschner N., Zielinski C., 2016

机译：贝伐单抗治疗HER2阴性的局部复发/转移性乳腺癌的一线贝伐单抗治疗进展后的TANIA TANIA随机III期临床试验的最终结果

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

摘要

著录项

相似文献

相关主题

期刊订阅